Advanced Life Sciences Holdings, Inc. to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference

CHICAGO, Nov. 20 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. today announced that it will present at the Lazard Capital Markets Fourth Annual Healthcare Conference which will be webcast live via streaming audio. Advanced Life Sciences’ management will provide an overview and update of the Company’s business.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

The Company’s presentation will be delivered at 2:00 PM to 2:30 PM with a breakout to follow from 2:30-3:00 PM Eastern Standard Time in the Campbell room on Tuesday, November 27, 2007 at The Palace Hotel in New York City. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, http://www.advancedlifesciences.com. Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences’ filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,
+1-630-754-4352, jcamp@advancedlifesciences.com; or media, Melanie Nimrodi,
+1-312-546-3508, mnimrodi@mww.com, or investors, Kathy Price,
+1-213-486-6547, kprice@frbir.com, both of Financial Relations Board, for
Advanced Life Sciences Holdings, Inc.

Web site: http://www.advancedlifesciences.com/

MORE ON THIS TOPIC